The DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index.
Is liraglutide safe and effective in the elderly obese patients?: A single center experience
Open accessAbstract
The prevalence of Obesity is increasing globally, including in Türkiye, and affects all age groups, including the elderly. Previous clinical trials have shown the efficacy and safety of liraglutide in reducing the body weight of older adults. This study aimed to evaluate the effectiveness of liraglutide on weight loss and to identify any adverse effects in elderly individuals with obesity. This retrospective cohort study included patients aged ≥ 60 years with a body-mass index (BMI) ≥ 27 or greater and other comorbidities, as well as those with an initial BMI ≥ 30. All patients referred from a private tertiary clinic were prescribed liraglutide for obesity treatment. Data were collected from September 2023 to September 2024, with metabolic and anthropometric parameters recorded at the first appointment, followed by the monitoring of body weight and adverse effects during treatment. The mean age of the 32 patients was 63.78 years (± 10.50 years), with 90.6% of patients being female. Their mean weight and BMI were 94.31 ± 14.82 kg and 36.49 ± 5.34 kg/m², respectively. The body weight loss percentages were 5.96% at week 4, 10.06% at week 8, 13.85% at week 12, and 15.80% at week 24 (all P < .0001). At week 24, 100% of the patients lost more than 5% and 10% of their initial weight, respectively. Nausea was the most common adverse effect observed, with no reported instances of pancreatitis. This study corroborates the findings of previous research in this field. Evidence indicates that liraglutide is both efficacious and safe for treating obesity in the elderly population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“32 patients aged > 60 years with obesity or overweight and at least one weight-related comorbidity experienced a 5–10% reduction in baseline body weight following 24 weeks of liraglutide treatment”
From GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenia and Sarcopenic Obesity (2026) · doi:10.1007/s13668-026-00777-x · cites this paper as [44]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
2024 ESC Guidelines for the management of elevated blood pressure and hypertension
McEvoy, J. W., McCarthy, C. P., Bruno, R. M., Brouwers, S., Canavan, M. D., Ceconi, C., Christodorescu, R. M., Daskalopoulou, S. S., Ferro, C. J., Gerdts, E., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae178 · Cited by 2,298
Obesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506 · cited 2×
“…due to the plethora of hormonal, metabolic, and neural alterations associated with obesity that are conducive to the reacquisition of lost mass. [5] Pharmacotherapy should be regarded as a vital component of a multifaceted, systematic disease management approach and is recommended for adults…”
Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies
Batsis, J. A., & Villareal, D. T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0062-9 · Cited by 1,382 · cited 1×
“[15] Obesity and aging are both characterized by a state of low-grade inflammation and alterations to the endocrine sys-tem.”
Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198
on behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842
Health consequences of obesity in the elderly: a review of four unresolved questions
Zamboni, M., Mazzali, G., Zoico, E., Harris, T. B., Meigs, J. B., Di Francesco, V, Fantin, F., Bissoli, L., & Bosello, O. (2005) · International Journal of Obesity · doi:10.1038/sj.ijo.0803005 · Cited by 649 · cited 1×
“[13,14] The evidence suggests that in both men and women, regardless of whether they are of normal weight or obese, body weight tends to increase until reaching a peak at approximately age at which this begins to manifest is 65 for men and later for women, with a subsequent decline as the age of…”
on behalf of the SCALE study group, Blackman, A., Foster, G. D., Zammit, G., Rosenberg, R., Aronne, L., Wadden, T., Claudius, B., Jensen, C. B., & Mignot, E. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.52 · Cited by 583
van Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.162 · Cited by 537
Cited by
(2026) · doi:10.1007/s13668-026-00777-x · Cited by 10
“…cohort study by Oral et al., 32 patients aged > 60 years with obesity or overweight and at least one weight-related comorbidity experienced a 5–10% reduction in baseline body weight following 24 weeks of liraglutide treatment, although body composition was not assessed in this study [ 44].”
Bahat, G., Önür, N. H., Türkmen, B. Ö., Tırnova, Ş. Z. Ş., Erdoğan, T., Özkök, S., Aliyev, S., Bakır, B., & Karan, M. A. (2026) · Nutrition · doi:10.1016/j.nut.2026.113253
GLP-1 Based Therapies for Obesity in Older Adults: Current Evidence and Emerging Treatments
Pendrey, A., Sierra, J. A. R., Alvarez, F. A., Muñoz, Y. M. F., & Sevilla‐Martir, J. (2026) · Global Journal of Obesity Diabetes and Metabolic Syndrome · doi:10.17352/gjodms.000071
Metadata
- Authors
- Oral, A., Küçük, C., & Kayalar, Y.
- Affiliations
- Biruni University (TR)
- Istanbul Florence Nightingale Hospital (TR)
- Corresponding author
- Küçük, Celalettin
- Venue
- Medicine
- Published
- 2025-04-18
- Volume
- 104
- Issue
- 16
- Pages
- e42155
- ISSN
- 0025-7974 (ISSN-L)
- 1536-5964
- PMC
- PMC12014040
- OpenAlex
- W4409696652
- Cited by
- 3
- References
- 21
- Citations by year
- 2026: 3
- FWCI
- 1.70
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Medicine (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- liraglutide, obesity, elderly patients, weight loss, GLP-1 receptor agonists, adverse effects, nausea, pancreatitis, body mass index
- MeSH terms
- Liraglutide, Aged, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Obesity, Retrospective Studies, Weight Loss, Body Mass Index, Treatment Outcome, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Is liraglutide safe and effective in the elderly obese patients?: A single center experience. https://app.cochat.ai/papers/10.1097/md.0000000000042155
- The paper
- Oral, A., Küçük, C., & Kayalar, Y. (2025). Is liraglutide safe and effective in the elderly obese patients?: A single center experience. Medicine. https://doi.org/10.1097/md.0000000000042155
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.